Literature DB >> 12462645

Antivascular tumor eradication by hypericin-mediated photodynamic therapy.

Bin Chen1, Tania Roskams, Peter A M de Witte.   

Abstract

Photodynamic therapy (PDT) with hypericin has been shown to inhibit tumor growth in different tumor models, and tumor vascular damage was suggested to be mainly responsible for the antitumoral effect. Here, we demonstrate tumor vascular damage and its consequence on local tumor control after hypericin-mediated PDT by using both short and long drug-light intervals. Radiation-induced fibrosarcoma-1 tumors were exposed to laser light at either 0.5 or 6 h after a 5 mg/kg dose of hypericin. Tumor perfusion was monitored by fluorescein dye-exclusion assay and by Hoechst 33342 staining of functional blood vessels. Significant reduction in tumor perfusion was found immediately after both PDT treatments. A complete arrest of vascular perfusion was detected by 15 h after the 0.5 h-interval PDT, whereas well-perfused areas could still be found at this time in tumors after the 6 h-interval PDT. A histological study confirmed that primary vascular damage was involved in both PDT treatments. Tumor cells appeared intact shortly after light treatment, degenerated at later hours and became extensively pycnotic at 24 h after the 0.5 h-interval PDT. PDT under this condition led to complete tumor cure. In contrast, significant numbers of viable tumor cells, especially at the tumor periphery, were found histologically at 24 h after the 6 h-interval PDT. No tumor cure was obtained when PDT was performed at this time. Our results strongly suggest that targeting the tumor vasculature by applying short drug-light interval PDT with hypericin might be a promising way to eradicate solid tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12462645     DOI: 10.1562/0031-8655(2002)076<0509:atebhm>2.0.co;2

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  21 in total

1.  Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.

Authors:  Theresa M Busch; Hsing-Wen Wang; E Paul Wileyto; Guoqiang Yu; Ralph M Bunte
Journal:  Radiat Res       Date:  2010-09       Impact factor: 2.841

2.  Successful in vivo tumor visualization using fluorescence laparoscopy in a mouse model of disseminated alveolar rhabdomyosarcoma.

Authors:  Cristian Urla; Sorin Armeanu-Ebinger; Jörg Fuchs; Guido Seitz
Journal:  Surg Endosc       Date:  2014-08-23       Impact factor: 4.584

Review 3.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

4.  Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2005-08-10       Impact factor: 3.631

5.  The effectiveness and safety of X-PDT for cutaneous squamous cell carcinoma and melanoma.

Authors:  Lei Shi; Pei Liu; Jing Wu; Lun Ma; Han Zheng; Michael P Antosh; Haiyan Zhang; Bo Wang; Wei Chen; Xiuli Wang
Journal:  Nanomedicine (Lond)       Date:  2019-06-05       Impact factor: 5.307

6.  Compartmental targeting for mTHPC-based photodynamic treatment in vivo: Correlation of efficiency, pharmacokinetics, and regional distribution of apoptosis.

Authors:  Julie Garrier; Aude Bressenot; Susanna Gräfe; Sophie Marchal; Soumya Mitra; Thomas H Foster; François Guillemin; Lina Bezdetnaya
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-23       Impact factor: 7.038

Review 7.  New photosensitizers for photodynamic therapy.

Authors:  Heidi Abrahamse; Michael R Hamblin
Journal:  Biochem J       Date:  2016-02-15       Impact factor: 3.857

8.  Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.

Authors:  Hing-Yuen Yeung; Pui-Chi Lo; Dennis K P Ng; Wing-Ping Fong
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

9.  Bypass of tumor drug resistance by antivascular therapy.

Authors:  Dina Preise; Ohad Mazor; Natalia Koudinova; Mordechai Liscovitch; Avigdor Scherz; Yoram Salomon
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

10.  Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.

Authors:  Junjie Li; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal:  J Cancer       Date:  2013-01-22       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.